Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jun 5;32(7):410.
doi: 10.1007/s00520-024-08579-z.

Effectiveness of increasing the scalp cooling duration to prevent alopecia during adjuvant chemotherapy for breast cancer: a randomized pilot study

Edith Carton  1 , Anne Mercier Blas  1 , Clément Perret  1 , Marcelle Le Bihan  2
Affiliations
Randomized Controlled Trial

Effectiveness of increasing the scalp cooling duration to prevent alopecia during adjuvant chemotherapy for breast cancer: a randomized pilot study

Edith Carton et al. Support Care Cancer. .

Abstract

Purpose: Alopecia is a common side-effect of chemotherapy and can be extremely distressing to patients. Scalp cooling can be used to reduce hair loss, but the optimal duration of cooling remains unclear. Our aim was to determine whether increasing the duration of scalp cooling improves hair preservation.

Methods: Patients with HER2-negative, non-metastatic, breast cancer received scalp cooling during adjuvant chemotherapy: three cycles of epirubicin/cyclophosphamide (EC) followed by three cycles of paclitaxel. The patients were randomly assigned to two groups. Group A (n=18) wore a Paxman cooling cap during each infusion and for 30 min post-infusion while Group B (n=19) wore the cap from 30 min before to 2 h after each infusion. All patients were asked to complete a questionnaire recording hair loss/regrowth, adverse events, and quality of life. Success of treatment was defined as <50% hair loss.

Results: The success rates after each of the three cycles did not differ significantly between the two groups (EC: Group A: 40%, Group B: 44%; paclitaxel: Group A: 50%, Group B: 36%; p>0.05). Hair regrowth was significantly higher in Group B at the 8-week follow-up, but not at the 6-month follow-up. Head discomfort affected more patients in Group B than in Group A during the first session (94% vs. 62%, respectively; p=0.039).

Conclusion: Long duration scalp cooling during chemotherapy might increase patients' discomfort and does not appear to improve hair preservation.

Keywords: Alopecia; Breast cancer; Chemotherapy; Hair preservation; Scalp cooling; Side-effects.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the study participants
Fig. 2
Fig. 2
Nurse’s ratings of the patients’ hair loss. The percentage of patients with each grade of alopecia, as determined by a nurse after three cycles of epirubicin + cyclophosphamide (EC), three cycles of paclitaxel, and at the 8-week and 6-month follow-ups. Grade 0 = no hair loss, grade 1 = <50% hair loss, grade 2 = >50% hair loss, and grade 3+ = total hair loss
Fig. 3
Fig. 3
Patients’ ratings of their hair loss. The percentage of patients with each self-rated hair loss after three cycles of epirubicin + cyclophosphamide (EC), three cycles of paclitaxel, and at the 8-week and 6-month follow-ups
See this image and copyright information in PMC

References

    1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15–23. doi: 10.1016/j.breast.2022.08.010. - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Trewin CB, Johansson ALV, Hjerkind KV, Strand BH, Kiserud CE, Ursin G. Stage-specific survival has improved for young breast cancer patients since 2000: but not equally. Breast Cancer Res Treat. 2020;182:477–489. doi: 10.1007/s10549-020-05698-z. - DOI - PMC - PubMed
    1. Moattari CR, Jafferany M. Psychological aspects of hair disorders: Consideration for dermatologists, cosmetologists, aesthetic, and plastic surgeons. Skin Appendage Disord. 2022;8:186–194. doi: 10.1159/000519817. - DOI - PMC - PubMed
    1. Chan J, Adderley H, Alameddine M, Armstrong A, Arundell D, Fox R, Harries M, Lim J, Salih Z, Tetlow C, Wong H, Thorp N. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care. 2021;30:e13395. doi: 10.1111/ecc.13395. - DOI - PubMed

Publication types

MeSH terms